Loading stock data…
CGON
$56.67+2.27 (+4.17%)
After Hours$56.67+0.00 (+0.00%)· Last close Jun 9
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CG Oncology, Inc. in the Healthcare sector is trading at $56.67 with a market capitalization of $5.5B. Wall Street consensus targets $90.29 (14 analysts), implying a +59.3% move over the next 12 months. The stock is currently 25% below its 52-week high of $75.50, remaining 11.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +59.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$56.67
Potential Downside
0%
Whystock Fair Value$56.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$90.29+59.3%
Range$80.00 – $108.00
Fundamentals
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigationa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.39%
Volume
Today's trading volume
1.22M
Recent News
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy cou
Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?
CG Oncology, Inc. has agreed to the separation of President & Chief Operating Officer Ambaw Bellete effective June 30, 2026, while appointing CEO Arthur Kuan as President and launching a search for a Chief Commercial Officer. This consolidation of leadership roles around Kuan, alongside an active search for commercial expertise, highlights a meaningful shift in how CG Oncology plans to manage execution and commercialization priorities. We’ll now examine how this leadership transition,...
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an
Sector Update: Healthcare Stocks Decline Tuesday Afternoon
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones. The discussio